Latest news
Xeltis raises an additional €20.5m of funding to advance aXess toward FDA approval and US commercial launch - Med-Tech InsightsMed-Tech Insights · Thu, 06 Aug 2026 08:31:23 GMTFDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS - OncLiveOncLive · Fri, 31 Jul 2026 07:00:00 GMT